Black Friday Deal: $15 OFF Forever on All Plans — Limited Time Only!
TARO logo
NYSE · TARODrug Manufacturers - Specialty & GenericUpdated Not supplied

Taro Pharmaceutical Industries Ltd. P/E ratio

Current valuation, historical context, and peer comparisons.

Current P/E ratio

30.05×

58.1% abovethe 9-observation annual average

Share price42.975
÷
Earnings per share1.43

Price and EPS in quote currency. Calculation details

Investors are paying 30.05 for every 1 of reported earnings per share.

P/E over time

2015 – 2024
Annual P/ESelected-period average 19.01×
3-year average31.07×3 positive annual observations
5-year average25.71×4 positive annual observations
10-year average19.01×9 positive annual observations
Peer median · TTM12.02×3 peers with positive P/E

Historical P/E ratios

Annual period-end data · 25 observations

TARO annual P/E history, newest first
Period endP/EChange
Mar 31, 202429.53×-17.4%
Mar 31, 202335.76×+28.1%
Mar 31, 202227.91×N/M
Mar 31, 2021N/MN/M
Mar 31, 20209.64×-36.0%
Mar 31, 201915.06×-19.8%
Mar 31, 201818.77×+77.9%
Mar 31, 201710.55×-7.0%
View all 25 annual observations +
TARO annual P/E history, newest first
Period endP/EChange
Mar 31, 201611.35×-9.0%
Mar 31, 201512.47×-8.6%
Mar 31, 201413.64×+38.6%
Mar 31, 20139.84×-72.6%
Mar 31, 201235.95×N/M
Dec 31, 2011N/MN/M
Dec 31, 20109.11×+198.6%
Dec 31, 20093.05×-69.1%
Dec 31, 20089.87×+26.9%
Dec 31, 20077.78×N/M
Dec 31, 2006N/MN/M
Dec 31, 200573.53×-17.9%
Dec 31, 200489.55×+194.3%
Dec 31, 200330.42×+25.4%
Dec 31, 200224.26×-32.6%
Dec 31, 200135.99×+8.9%
Dec 31, 200033.05×N/M

Change is relative to the preceding observation. N/M values are excluded from averages.

How TARO compares

Company P/E vs. peer trailing-12-month ratios

P/E comparison with TARO and provider-selected peers
CompanyP/E ratio
TARO logo
TARO This stockTaro Pharmaceutical Industries Ltd.
30.05×
VIVO logo
VIVOVivoPower PLC
N/M
EMBC logo
EMBCEmbecta Corp.
4.04×
ASTH logo
ASTHAstrana Health, Inc.
26.76×
NXGN logo
NXGNNextGen Healthcare, Inc.
N/M
AMAM logo
AMAMAmbrx Biopharma Inc.
N/M
DCPH logo
DCPHDeciphera Pharmaceuticals, Inc.
N/M
PNT logo
PNTPOINT Biopharma Global Inc.
12.02×
FUSN logo
FUSNFusion Pharmaceuticals Inc.
N/M

Peers are selected by the data provider. Business models and earnings definitions can differ.

Put the numbers in context

What does TARO’s P/E tell you?

01

Start with its own history

At 30.05×, TARO is 58.1% above its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

02

Compare like with like

The median of the 3 positive peer ratios above is 12.02×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.

03

Check what drives earnings

One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.

Keep your research connected

Take TARO into your spreadsheet

Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.

Explore Wisesheets
Quarterly P/E · latest quarter
=WISE("TARO", "PE Ratio", "LQ")
LQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data

Sources & calculation methodology

Current P/E

Share price 42.975 ÷ EPS 1.43 = 30.05×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.

History & averages

Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.

Data definitions and limitations

The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.

TARO P/E ratio: common questions

The essentials behind the numbers.

Taro Pharmaceutical Industries Ltd.'s current P/E is 30.05× based on the quote data last updated Not supplied. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.